JP2009540852A5 - - Google Patents

Download PDF

Info

Publication number
JP2009540852A5
JP2009540852A5 JP2009517228A JP2009517228A JP2009540852A5 JP 2009540852 A5 JP2009540852 A5 JP 2009540852A5 JP 2009517228 A JP2009517228 A JP 2009517228A JP 2009517228 A JP2009517228 A JP 2009517228A JP 2009540852 A5 JP2009540852 A5 JP 2009540852A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
antigen
nos
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/056584 external-priority patent/WO2008003656A2/en
Publication of JP2009540852A publication Critical patent/JP2009540852A/ja
Publication of JP2009540852A5 publication Critical patent/JP2009540852A5/ja
Pending legal-status Critical Current

Links

JP2009517228A 2006-07-03 2007-06-29 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用 Pending JP2009540852A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81768606P 2006-07-03 2006-07-03
PCT/EP2007/056584 WO2008003656A2 (en) 2006-07-03 2007-06-29 Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics

Publications (2)

Publication Number Publication Date
JP2009540852A JP2009540852A (ja) 2009-11-26
JP2009540852A5 true JP2009540852A5 (enExample) 2010-08-05

Family

ID=38537749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517228A Pending JP2009540852A (ja) 2006-07-03 2007-06-29 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用

Country Status (10)

Country Link
US (1) US20120141376A1 (enExample)
EP (1) EP2044216A2 (enExample)
JP (1) JP2009540852A (enExample)
KR (1) KR20090111307A (enExample)
CN (1) CN101506376A (enExample)
AU (1) AU2007271232A1 (enExample)
CA (1) CA2656140A1 (enExample)
IL (1) IL196184A0 (enExample)
WO (1) WO2008003656A2 (enExample)
ZA (1) ZA200900794B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1007704A2 (pt) * 2009-05-12 2019-12-03 Koninklijke Philips Electronics N.V. fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
DE102012203547A1 (de) * 2012-03-07 2013-09-12 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Antimikrobielle Peptide
JP6308954B2 (ja) * 2012-03-05 2018-04-11 オサケユキテュア・アークティック・パートナーズ・アクチボラゲットOy Arctic Partners Ab 前立腺癌のリスク及び前立腺容積を予測する方法及び装置
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
JP6815331B2 (ja) * 2015-04-21 2021-01-20 ジェネンテック, インコーポレイテッド 前立腺がんの分析のための組成物及び方法
CA2982262A1 (en) 2015-04-29 2016-11-03 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
JP2018526005A (ja) * 2015-09-02 2018-09-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 前立腺がんのげっ歯類モデル
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
US11410748B2 (en) * 2018-02-22 2022-08-09 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
EP3958879A4 (en) * 2019-04-25 2023-05-10 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN111383757B (zh) * 2020-03-04 2023-08-25 南京亿科人群健康研究院有限公司 一种计算机辅助开发包虫病诊断试剂盒的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
AU3305699A (en) * 1998-02-26 1999-09-15 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
WO2001055448A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
JP2005519606A (ja) * 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−2及びカリクレイン−3のバリアント並びにそれらの使用
WO2004113571A2 (en) * 2003-06-26 2004-12-29 Exonhit Therapeutics Sa Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis

Similar Documents

Publication Publication Date Title
JP2005504513A5 (enExample)
Gallotta et al. Inhaled TLR9 agonist renders lung tumors permissive to PD-1 blockade by promoting optimal CD4+ and CD8+ T-cell interplay
US20190345228A1 (en) Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
CA3110923A1 (en) Process for preparing vaccine compositions
JP2006515749A5 (enExample)
JP2021514178A5 (enExample)
DK1759013T3 (da) Identificering af overflade-associerede antigener til tumordiagnose
JP2018509135A5 (enExample)
JP2019502360A5 (enExample)
AU2015249374A1 (en) Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
JP2010516290A5 (enExample)
CA2402017A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
JP2009039107A5 (enExample)
KR20210086612A (ko) 펩타이드 백신
JP2008118915A (ja) 胃癌高発現遺伝子特定による胃癌診断および創薬への利用
JP2012520663A5 (enExample)
JP2023085493A (ja) 分子誘導システムペプチド及びその使用
EP2227558A1 (en) Method for classifying cancer patients as responder or non-responder to immunotherapy
RU2016138428A (ru) Пептиды neil3 и включающие их вакцины
KR20130055553A (ko) 환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법
CN107551264B (zh) L3和/或l5源作为寄生虫病疫苗或诊断的用途
WO2004067564B1 (en) Compositions against cancer antigen liv-1 and uses thereof
CN102498219A (zh) 在得自对象的生物学样品中评价癌症的方法
WO2004046376A2 (en) Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia (b-cll)
KR101759401B1 (ko) 스핑크1 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도